Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis
Currently chondroitin sulfate (CS) is the most studied drug from the group of «chondroprotectors». The article shows the role of CS in the treatment of osteoarthritis (OA): mechanism of action, clinical efficacy and safety in patients with OA with comorbidity. Evidence for the effectiveness and safe...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-08-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242166528835584 |
|---|---|
| author | E. P. Sharapova E. A. Taskina N. G. Kashevarova L. I. Alekseeva A. M. Lila |
| author_facet | E. P. Sharapova E. A. Taskina N. G. Kashevarova L. I. Alekseeva A. M. Lila |
| author_sort | E. P. Sharapova |
| collection | DOAJ |
| description | Currently chondroitin sulfate (CS) is the most studied drug from the group of «chondroprotectors». The article shows the role of CS in the treatment of osteoarthritis (OA): mechanism of action, clinical efficacy and safety in patients with OA with comorbidity. Evidence for the effectiveness and safety of the use of CS has been analyzed. The place of this drug in Russian and international clinical guidelines for the management of patients with OA is discussed.In domestic practice, the parenteral form of CS is often used in patients with OA. The parenteral form of CS for intramuscular and intra-articular administration (Chondroguard®) has a number of advantages, including the rapid onset of the effect. This enables reducing the dose in a short time or completely abandon the use of non-steroidal anti-inflammatory drugs (NSAIDs), which is extremely important for patients with OA with comorbidity. Chondroguard® can be recommended for initial use in exacerbations of chronic joint and back pain in OA, including in patients with relative and absolute contraindications for NSAID therapy. |
| format | Article |
| id | doaj-art-eb0d8ed317034dfcbaf48f34db740145 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2021-08-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-eb0d8ed317034dfcbaf48f34db7401452025-08-20T03:59:54ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2021-08-0115412012510.14412/1996-7012-2021-4-120-1252391Efficacy of Chondroitin Sulfate in Patients with Knee and Hip OsteoarthritisE. P. Sharapova0E. A. Taskina1N. G. Kashevarova2L. I. Alekseeva3A. M. Lila4V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationCurrently chondroitin sulfate (CS) is the most studied drug from the group of «chondroprotectors». The article shows the role of CS in the treatment of osteoarthritis (OA): mechanism of action, clinical efficacy and safety in patients with OA with comorbidity. Evidence for the effectiveness and safety of the use of CS has been analyzed. The place of this drug in Russian and international clinical guidelines for the management of patients with OA is discussed.In domestic practice, the parenteral form of CS is often used in patients with OA. The parenteral form of CS for intramuscular and intra-articular administration (Chondroguard®) has a number of advantages, including the rapid onset of the effect. This enables reducing the dose in a short time or completely abandon the use of non-steroidal anti-inflammatory drugs (NSAIDs), which is extremely important for patients with OA with comorbidity. Chondroguard® can be recommended for initial use in exacerbations of chronic joint and back pain in OA, including in patients with relative and absolute contraindications for NSAID therapy.https://mrj.ima-press.net/mrj/article/view/1181knee and hip osteoarthritischondroitin sulfatechondroguardefficiencysafetyadverse events |
| spellingShingle | E. P. Sharapova E. A. Taskina N. G. Kashevarova L. I. Alekseeva A. M. Lila Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis Современная ревматология knee and hip osteoarthritis chondroitin sulfate chondroguard efficiency safety adverse events |
| title | Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis |
| title_full | Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis |
| title_fullStr | Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis |
| title_full_unstemmed | Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis |
| title_short | Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis |
| title_sort | efficacy of chondroitin sulfate in patients with knee and hip osteoarthritis |
| topic | knee and hip osteoarthritis chondroitin sulfate chondroguard efficiency safety adverse events |
| url | https://mrj.ima-press.net/mrj/article/view/1181 |
| work_keys_str_mv | AT epsharapova efficacyofchondroitinsulfateinpatientswithkneeandhiposteoarthritis AT eataskina efficacyofchondroitinsulfateinpatientswithkneeandhiposteoarthritis AT ngkashevarova efficacyofchondroitinsulfateinpatientswithkneeandhiposteoarthritis AT lialekseeva efficacyofchondroitinsulfateinpatientswithkneeandhiposteoarthritis AT amlila efficacyofchondroitinsulfateinpatientswithkneeandhiposteoarthritis |